188 related articles for article (PubMed ID: 31524993)
1. Botulinum Toxin in the Long-Term Treatment of Refractory Raynaud’s Phenomenon.
Asad U; Austin B; Tarbox M; Paulger B
J Drugs Dermatol; 2019 Sep; 18(9):943-945. PubMed ID: 31524993
[TBL] [Abstract][Full Text] [Related]
2. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
4. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
[TBL] [Abstract][Full Text] [Related]
6. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
[TBL] [Abstract][Full Text] [Related]
8. [Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin].
Roguedas AM; Misery L
Ann Dermatol Venereol; 2014; 141(6-7):462-3. PubMed ID: 24951147
[No Abstract] [Full Text] [Related]
9. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
[TBL] [Abstract][Full Text] [Related]
11. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
Zhao H; Lian Y
Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin for refractory Raynaud's phenomenon: A "how to" guide for pediatric patients.
Barry KK; Reusch DB; Shahriari N; Lonowski S; Dedeoglu F; Vleugels RA
Pediatr Dermatol; 2023; 40(3):587-589. PubMed ID: 36840449
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
Uppal L; Dhaliwal K; Butler PE
J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
[TBL] [Abstract][Full Text] [Related]
18. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
[TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
Quintana Castanedo L; Feito Rodríguez M; Nieto Rodríguez D; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Dermatol Surg; 2021 Jan; 47(1):61-64. PubMed ID: 32371783
[TBL] [Abstract][Full Text] [Related]
20. Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection.
Navarro EP; Cañas CA; Tobón GJ
Rheumatology (Oxford); 2016 Jul; 55(7):1216. PubMed ID: 27155203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
